Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Dec 2021
Ascletis announces inclusion in new catalogue of China National Reimbursement Drug List of Asclevir/Ganovo regimen, an all oral direct anti-HCV therapy
2 December 2021 - Ascletis Pharma today announces that its all-oral direct anti-hepatitis C virus Asclevir (ravidasvir)/Ganovo (danoprevir) regimen has been ...
Posted by Michael Wonder on 07 Dec 2021
Critics blame diabetes deaths on PHARMAC taking years to fund new drug
6 December 2021 - Diabetes Foundation Aotearoa says PHARMAC's delay funding new diabetes drugs has led to many deaths in Māori ...
Posted by Michael Wonder on 07 Dec 2021
BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib
2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement ...
Posted by Michael Wonder on 07 Dec 2021
Shining a light on PHARMAC
6 December 2021 - It is encouraging to read the country’s drug buying agency PHARMAC is already moving to improve ...
Posted by Michael Wonder on 07 Dec 2021
Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma. ...
Posted by Michael Wonder on 06 Dec 2021
Theratechnologies submits supplemental biologics license application to FDA advancing development of IV push Trogarzo for patients living with HIV
6 December 2021 - sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results. ...
Posted by Michael Wonder on 06 Dec 2021
Sapience Therapeutics receives FDA fast track designation for ST101 for the treatment of recurrent glioblastoma multiforme
6 December 2021 - Sapience Therapeutics announced today that the U.S. FDA has granted fast track designation to its lead ...
Posted by Michael Wonder on 06 Dec 2021
HCF calls for independent regulator of medical devices
6 December 2021 - Health insurer HCF has raised concerns that some doctors may be deciding what device to implant ...
Posted by Michael Wonder on 06 Dec 2021
EMA recommends approval for use of RoActemra in adults with severe COVID-19
6 December 2021 - The EMA’s CHMP has recommended extending the indication of RoActemra (tocilizumab) to include the treatment of ...
Posted by Michael Wonder on 06 Dec 2021
TGA provisional approval of Celltrion COVID-19 treatment regdanvimab (Regkirona)
6 December 2021 - On 6 December 2021, the TGA granted provisional approval to Celltrion Healthcare for the use of ...
Posted by Michael Wonder on 06 Dec 2021
PHARMAC negotiates deal with Pfizer for its promising new oral antiviral treatment for COVID-19
6 December 2021 - PHARMAC has negotiated an agreement with Pfizer for its promising new oral anti-viral treatment to treat ...
Posted by Michael Wonder on 06 Dec 2021
Secura Bio announces Copiktra (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S. withdrawal of the relapsed or refractory follicular lymphoma indication
3 December 2021 - Secura Bio has voluntarily withdrawn the U.S. Copiktra indication for the treatment of patients with relapsed or ...
Posted by Michael Wonder on 06 Dec 2021
Chiesi Global Rare Diseases announces updated U.S. Prescribing Information for Ferriprox (deferiprone)
3 December 2021 - Chiesi Global Rare Diseases announced today that the Ferriprox (deferiprone) Prescribing Information in the U.S. has been ...
Posted by Michael Wonder on 05 Dec 2021
RefleXion receives breakthrough device designation for lung cancer treatment
1 December 2021 - RefleXion Medical today announced that the U.S. FDA has granted the company breakthrough device designation for ...
Posted by Michael Wonder on 05 Dec 2021
FDA approves new Kyprolis (carfilzomib) combination regimen with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and dexamethasone for patients with multiple myeloma at first or subsequent relapse
1 December 2021 - Kyprolis in combination with subcutaneous treatment regimen provides further options and convenience for patients with relapsed/refractory ...